| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 127 | 2024 | 136 | 18.050 |
Why?
|
| Polymorphism, Single Nucleotide | 132 | 2024 | 348 | 9.770 |
Why?
|
| Neoplasms, Glandular and Epithelial | 48 | 2018 | 49 | 6.850 |
Why?
|
| Genetic Predisposition to Disease | 84 | 2024 | 231 | 6.700 |
Why?
|
| Genome-Wide Association Study | 70 | 2024 | 190 | 6.170 |
Why?
|
| Humans | 268 | 2024 | 6896 | 5.380 |
Why?
|
| Transcriptome | 14 | 2024 | 59 | 5.250 |
Why?
|
| Neoplasms | 15 | 2024 | 128 | 5.220 |
Why?
|
| Female | 195 | 2024 | 3525 | 4.390 |
Why?
|
| Gene Expression Profiling | 24 | 2024 | 126 | 4.370 |
Why?
|
| Computational Biology | 15 | 2024 | 43 | 3.630 |
Why?
|
| Models, Genetic | 16 | 2018 | 33 | 3.400 |
Why?
|
| Middle Aged | 94 | 2024 | 608 | 2.960 |
Why?
|
| Biomarkers, Tumor | 25 | 2023 | 65 | 2.900 |
Why?
|
| Breast Neoplasms | 20 | 2022 | 38 | 2.660 |
Why?
|
| High-Throughput Nucleotide Sequencing | 9 | 2018 | 99 | 2.630 |
Why?
|
| Genotype | 76 | 2022 | 410 | 2.590 |
Why?
|
| Gene Expression Regulation, Neoplastic | 25 | 2024 | 59 | 2.560 |
Why?
|
| Aged | 76 | 2024 | 378 | 2.500 |
Why?
|
| Case-Control Studies | 70 | 2023 | 215 | 2.340 |
Why?
|
| Sequence Analysis, RNA | 7 | 2023 | 26 | 2.330 |
Why?
|
| Bayes Theorem | 14 | 2018 | 30 | 2.150 |
Why?
|
| Antineoplastic Agents | 15 | 2019 | 55 | 2.130 |
Why?
|
| DNA Methylation | 17 | 2019 | 115 | 2.110 |
Why?
|
| Models, Statistical | 10 | 2018 | 29 | 2.100 |
Why?
|
| Phenotype | 27 | 2023 | 257 | 2.060 |
Why?
|
| Genomics | 12 | 2023 | 101 | 2.000 |
Why?
|
| Genetic Association Studies | 23 | 2019 | 53 | 1.990 |
Why?
|
| Cluster Analysis | 16 | 2023 | 43 | 1.950 |
Why?
|
| Algorithms | 9 | 2022 | 105 | 1.920 |
Why?
|
| Genetic Variation | 21 | 2016 | 174 | 1.850 |
Why?
|
| Cell Line, Tumor | 25 | 2024 | 99 | 1.840 |
Why?
|
| Software | 8 | 2024 | 30 | 1.830 |
Why?
|
| Adult | 66 | 2024 | 1181 | 1.820 |
Why?
|
| Single-Cell Analysis | 3 | 2024 | 18 | 1.820 |
Why?
|
| Cystadenocarcinoma, Serous | 13 | 2018 | 13 | 1.780 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 26 | 1.720 |
Why?
|
| Risk Factors | 55 | 2024 | 487 | 1.700 |
Why?
|
| Deoxycytidine | 14 | 2020 | 14 | 1.700 |
Why?
|
| Gene Expression | 9 | 2023 | 67 | 1.570 |
Why?
|
| Pharmacogenetics | 17 | 2016 | 176 | 1.560 |
Why?
|
| Endometrial Neoplasms | 12 | 2022 | 12 | 1.500 |
Why?
|
| Computer Simulation | 11 | 2018 | 31 | 1.470 |
Why?
|
| Glioma | 6 | 2023 | 28 | 1.390 |
Why?
|
| Signal Transduction | 14 | 2024 | 132 | 1.300 |
Why?
|
| Glioblastoma | 7 | 2022 | 17 | 1.290 |
Why?
|
| Aged, 80 and over | 36 | 2020 | 151 | 1.280 |
Why?
|
| Genome, Human | 15 | 2023 | 86 | 1.270 |
Why?
|
| Adenocarcinoma, Clear Cell | 7 | 2018 | 7 | 1.170 |
Why?
|
| Prognosis | 28 | 2023 | 211 | 1.170 |
Why?
|
| Male | 50 | 2023 | 3337 | 1.130 |
Why?
|
| Genetic Loci | 13 | 2022 | 40 | 1.130 |
Why?
|
| Antimetabolites, Antineoplastic | 9 | 2016 | 26 | 1.100 |
Why?
|
| Tumor Microenvironment | 8 | 2024 | 17 | 1.090 |
Why?
|
| Databases, Genetic | 11 | 2021 | 30 | 1.080 |
Why?
|
| Gene Expression Regulation | 7 | 2022 | 101 | 1.080 |
Why?
|
| Prostatic Neoplasms | 7 | 2023 | 34 | 1.000 |
Why?
|
| Alleles | 28 | 2019 | 214 | 1.000 |
Why?
|
| Data Interpretation, Statistical | 6 | 2021 | 20 | 0.940 |
Why?
|
| Estradiol | 4 | 2018 | 9 | 0.890 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2018 | 3 | 0.880 |
Why?
|
| Linkage Disequilibrium | 16 | 2016 | 34 | 0.870 |
Why?
|
| Proteome | 1 | 2023 | 3 | 0.870 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2022 | 31 | 0.860 |
Why?
|
| Proteomics | 4 | 2023 | 24 | 0.850 |
Why?
|
| Young Adult | 22 | 2023 | 647 | 0.840 |
Why?
|
| Biomarkers | 9 | 2023 | 136 | 0.840 |
Why?
|
| Colorectal Neoplasms | 6 | 2015 | 29 | 0.830 |
Why?
|
| Chromosomes, Human, Pair 8 | 9 | 2016 | 11 | 0.830 |
Why?
|
| DNA-Binding Proteins | 9 | 2015 | 39 | 0.820 |
Why?
|
| Databases, Factual | 2 | 2013 | 108 | 0.820 |
Why?
|
| Germ-Line Mutation | 7 | 2016 | 10 | 0.770 |
Why?
|
| Nuclear Proteins | 9 | 2016 | 52 | 0.740 |
Why?
|
| Quantitative Trait Loci | 13 | 2018 | 65 | 0.740 |
Why?
|
| Genetic Markers | 6 | 2016 | 22 | 0.740 |
Why?
|
| DNA Copy Number Variations | 3 | 2019 | 37 | 0.710 |
Why?
|
| Drug Design | 1 | 2019 | 7 | 0.690 |
Why?
|
| Thioguanine | 4 | 2014 | 8 | 0.680 |
Why?
|
| Brain Neoplasms | 6 | 2022 | 45 | 0.680 |
Why?
|
| Reproducibility of Results | 8 | 2024 | 199 | 0.670 |
Why?
|
| Normal Distribution | 2 | 2018 | 4 | 0.670 |
Why?
|
| Mutation | 10 | 2018 | 212 | 0.660 |
Why?
|
| Risk | 17 | 2023 | 41 | 0.650 |
Why?
|
| RNA, Messenger | 13 | 2017 | 115 | 0.640 |
Why?
|
| Mendelian Randomization Analysis | 6 | 2024 | 8 | 0.640 |
Why?
|
| Rare Diseases | 1 | 2019 | 48 | 0.640 |
Why?
|
| Genes, Neoplasm | 3 | 2015 | 4 | 0.630 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2018 | 1 | 0.630 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 3 | 0.620 |
Why?
|
| Organic Cation Transporter 1 | 1 | 2018 | 4 | 0.620 |
Why?
|
| Renin-Angiotensin System | 1 | 2018 | 5 | 0.620 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2018 | 15 | 0.620 |
Why?
|
| Bone Neoplasms | 4 | 2023 | 23 | 0.620 |
Why?
|
| Sex Factors | 1 | 2018 | 68 | 0.610 |
Why?
|
| Sarcoma, Ewing | 4 | 2022 | 7 | 0.610 |
Why?
|
| BRCA2 Protein | 6 | 2019 | 8 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 8 | 0.590 |
Why?
|
| Neoplasm Grading | 13 | 2017 | 19 | 0.590 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 7 | 0.590 |
Why?
|
| Genetic Linkage | 6 | 2012 | 12 | 0.590 |
Why?
|
| BRCA1 Protein | 5 | 2019 | 8 | 0.570 |
Why?
|
| Neoplasm Proteins | 6 | 2016 | 31 | 0.570 |
Why?
|
| Neoplasm Staging | 14 | 2021 | 33 | 0.570 |
Why?
|
| Drug Discovery | 1 | 2016 | 4 | 0.560 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 7 | 0.560 |
Why?
|
| Cisplatin | 2 | 2013 | 10 | 0.560 |
Why?
|
| Multifactorial Inheritance | 3 | 2008 | 17 | 0.540 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 304 | 0.540 |
Why?
|
| Gene-Environment Interaction | 6 | 2018 | 13 | 0.530 |
Why?
|
| Polymorphism, Genetic | 8 | 2015 | 90 | 0.530 |
Why?
|
| CpG Islands | 8 | 2018 | 53 | 0.520 |
Why?
|
| Carcinoma | 3 | 2023 | 7 | 0.520 |
Why?
|
| Leukocytes | 2 | 2018 | 3 | 0.510 |
Why?
|
| Logistic Models | 14 | 2019 | 84 | 0.500 |
Why?
|
| Neoplasm Invasiveness | 11 | 2014 | 29 | 0.500 |
Why?
|
| Obesity | 5 | 2016 | 125 | 0.500 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 71 | 0.500 |
Why?
|
| Disease-Free Survival | 9 | 2018 | 45 | 0.480 |
Why?
|
| Pancreatic Neoplasms | 5 | 2016 | 13 | 0.480 |
Why?
|
| Telomerase | 5 | 2014 | 5 | 0.480 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 12 | 2017 | 47 | 0.470 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2024 | 4 | 0.470 |
Why?
|
| Cell Line | 10 | 2014 | 81 | 0.470 |
Why?
|
| Smallpox Vaccine | 1 | 2013 | 1 | 0.460 |
Why?
|
| Survival Rate | 8 | 2018 | 83 | 0.460 |
Why?
|
| NF-kappa B | 4 | 2014 | 14 | 0.450 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2018 | 41 | 0.450 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 4 | 0.440 |
Why?
|
| Epigenesis, Genetic | 9 | 2019 | 68 | 0.440 |
Why?
|
| Meningeal Neoplasms | 2 | 2024 | 4 | 0.440 |
Why?
|
| Macular Degeneration | 6 | 2010 | 6 | 0.440 |
Why?
|
| Proteins | 4 | 2018 | 27 | 0.440 |
Why?
|
| Proportional Hazards Models | 10 | 2022 | 34 | 0.440 |
Why?
|
| Lung Neoplasms | 4 | 2015 | 23 | 0.430 |
Why?
|
| Principal Component Analysis | 4 | 2014 | 14 | 0.430 |
Why?
|
| Animals | 7 | 2024 | 729 | 0.430 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 11 | 0.430 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2022 | 6 | 0.420 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2018 | 6 | 0.420 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2018 | 15 | 0.420 |
Why?
|
| Survival Analysis | 10 | 2024 | 50 | 0.420 |
Why?
|
| Sensory Receptor Cells | 1 | 2012 | 1 | 0.420 |
Why?
|
| Ketone Bodies | 1 | 2012 | 2 | 0.420 |
Why?
|
| Alcoholism | 1 | 2012 | 4 | 0.420 |
Why?
|
| Promoter Regions, Genetic | 10 | 2019 | 49 | 0.410 |
Why?
|
| Multiple Myeloma | 3 | 2023 | 4 | 0.410 |
Why?
|
| Haplotypes | 15 | 2021 | 91 | 0.410 |
Why?
|
| Gene Frequency | 11 | 2019 | 90 | 0.400 |
Why?
|
| Purines | 1 | 2011 | 1 | 0.400 |
Why?
|
| Antimetabolites | 1 | 2011 | 4 | 0.400 |
Why?
|
| Pyrimidines | 1 | 2011 | 7 | 0.400 |
Why?
|
| Chromosome Mapping | 6 | 2014 | 35 | 0.400 |
Why?
|
| Sarcoma | 2 | 2022 | 6 | 0.390 |
Why?
|
| Disease | 1 | 2011 | 7 | 0.380 |
Why?
|
| Adolescent | 14 | 2022 | 2197 | 0.380 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 3 | 2016 | 5 | 0.370 |
Why?
|
| Smoking | 4 | 2017 | 22 | 0.370 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2022 | 19 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 94 | 0.370 |
Why?
|
| Cohort Studies | 12 | 2021 | 289 | 0.370 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2010 | 39 | 0.370 |
Why?
|
| Colonic Polyps | 1 | 2010 | 5 | 0.360 |
Why?
|
| Gene Regulatory Networks | 3 | 2016 | 16 | 0.360 |
Why?
|
| Mastectomy, Segmental | 2 | 2020 | 4 | 0.360 |
Why?
|
| MicroRNAs | 4 | 2017 | 27 | 0.360 |
Why?
|
| Metformin | 2 | 2022 | 5 | 0.350 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 11 | 0.350 |
Why?
|
| Liver | 4 | 2018 | 126 | 0.350 |
Why?
|
| Body Mass Index | 5 | 2016 | 157 | 0.340 |
Why?
|
| Treatment Outcome | 10 | 2019 | 622 | 0.340 |
Why?
|
| Aromatase | 3 | 2015 | 4 | 0.330 |
Why?
|
| Heat-Shock Proteins | 3 | 2018 | 7 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 66 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2014 | 3 | 0.330 |
Why?
|
| Endometriosis | 3 | 2015 | 4 | 0.320 |
Why?
|
| Odds Ratio | 11 | 2018 | 51 | 0.320 |
Why?
|
| Adenocarcinoma | 3 | 2013 | 9 | 0.320 |
Why?
|
| Models, Theoretical | 3 | 2020 | 13 | 0.320 |
Why?
|
| Exercise | 3 | 2016 | 140 | 0.310 |
Why?
|
| Tacrolimus Binding Proteins | 3 | 2013 | 6 | 0.310 |
Why?
|
| Fatigue | 2 | 2018 | 15 | 0.310 |
Why?
|
| Cytarabine | 4 | 2014 | 23 | 0.300 |
Why?
|
| Retrospective Studies | 10 | 2023 | 1296 | 0.300 |
Why?
|
| Inflammation | 5 | 2015 | 51 | 0.290 |
Why?
|
| Disease Susceptibility | 3 | 2018 | 11 | 0.290 |
Why?
|
| Disease Progression | 4 | 2016 | 111 | 0.290 |
Why?
|
| RNA, Small Interfering | 7 | 2016 | 22 | 0.290 |
Why?
|
| Receptors, Progesterone | 4 | 2020 | 10 | 0.280 |
Why?
|
| Metabolomics | 3 | 2023 | 18 | 0.280 |
Why?
|
| Genes, BRCA1 | 4 | 2015 | 6 | 0.280 |
Why?
|
| Pedigree | 4 | 2019 | 59 | 0.280 |
Why?
|
| Carboplatin | 4 | 2015 | 5 | 0.280 |
Why?
|
| Research Design | 3 | 2015 | 63 | 0.280 |
Why?
|
| Quality Control | 3 | 2023 | 8 | 0.270 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2016 | 2 | 0.270 |
Why?
|
| Cell Cycle | 3 | 2012 | 18 | 0.270 |
Why?
|
| Osteosarcoma | 2 | 2023 | 19 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2010 | 5 | 0.270 |
Why?
|
| Stromal Cells | 2 | 2024 | 3 | 0.260 |
Why?
|
| Monte Carlo Method | 3 | 2012 | 5 | 0.260 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2015 | 2 | 0.260 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2015 | 2 | 0.260 |
Why?
|
| Docosahexaenoic Acids | 2 | 2015 | 3 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2016 | 7 | 0.260 |
Why?
|
| Transcription Factors | 5 | 2019 | 52 | 0.260 |
Why?
|
| Genes, BRCA2 | 3 | 2015 | 5 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2016 | 6 | 0.260 |
Why?
|
| Antigens, CD | 3 | 2011 | 8 | 0.250 |
Why?
|
| Thymidylate Synthase | 2 | 2018 | 2 | 0.250 |
Why?
|
| United States | 9 | 2022 | 669 | 0.250 |
Why?
|
| DNA, Mitochondrial | 4 | 2022 | 5 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2014 | 4 | 0.250 |
Why?
|
| Taxoids | 3 | 2014 | 3 | 0.250 |
Why?
|
| Gene Silencing | 2 | 2016 | 13 | 0.250 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2022 | 21 | 0.250 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2024 | 1 | 0.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 15 | 0.240 |
Why?
|
| Immunotherapy | 1 | 2024 | 16 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2018 | 8 | 0.240 |
Why?
|
| Spatial Analysis | 1 | 2024 | 2 | 0.240 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 8 | 0.240 |
Why?
|
| Membrane Proteins | 2 | 2014 | 54 | 0.240 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 4 | 2014 | 7 | 0.240 |
Why?
|
| Melanoma | 1 | 2024 | 12 | 0.240 |
Why?
|
| Prospective Studies | 7 | 2023 | 525 | 0.240 |
Why?
|
| Linear Models | 1 | 2024 | 56 | 0.240 |
Why?
|
| Statistics as Topic | 3 | 2016 | 18 | 0.240 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 45 | 0.230 |
Why?
|
| Mass Spectrometry | 2 | 2023 | 18 | 0.230 |
Why?
|
| Child | 7 | 2023 | 3364 | 0.230 |
Why?
|
| Aspirin | 1 | 2023 | 5 | 0.230 |
Why?
|
| Meta-Analysis as Topic | 6 | 2023 | 14 | 0.220 |
Why?
|
| Estrogen Receptor alpha | 2 | 2015 | 8 | 0.220 |
Why?
|
| Interleukin-1alpha | 2 | 2013 | 2 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 26 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2013 | 7 | 0.220 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2013 | 20 | 0.210 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 2 | 0.210 |
Why?
|
| Genetic Testing | 2 | 2020 | 87 | 0.210 |
Why?
|
| Leukopenia | 1 | 2022 | 1 | 0.210 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 6 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 50 | 0.210 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2019 | 2 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 12 | 3 | 2012 | 5 | 0.210 |
Why?
|
| Pyroptosis | 2 | 2021 | 4 | 0.210 |
Why?
|
| Genes, X-Linked | 2 | 2019 | 3 | 0.210 |
Why?
|
| 5'-Nucleotidase | 2 | 2013 | 2 | 0.210 |
Why?
|
| X Chromosome Inactivation | 2 | 2019 | 3 | 0.210 |
Why?
|
| Markov Chains | 3 | 2012 | 8 | 0.210 |
Why?
|
| Natural Language Processing | 1 | 2022 | 3 | 0.210 |
Why?
|
| Astrocytoma | 2 | 2012 | 5 | 0.200 |
Why?
|
| Stochastic Processes | 3 | 2012 | 4 | 0.200 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 8 | 0.200 |
Why?
|
| Meningioma | 1 | 2021 | 2 | 0.200 |
Why?
|
| RNA, Long Noncoding | 3 | 2019 | 14 | 0.200 |
Why?
|
| Lymphocytes | 3 | 2012 | 15 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2018 | 58 | 0.200 |
Why?
|
| Triglycerides | 2 | 2020 | 22 | 0.200 |
Why?
|
| Folic Acid | 4 | 2014 | 17 | 0.190 |
Why?
|
| Genetics, Population | 2 | 2019 | 11 | 0.190 |
Why?
|
| Inflammasomes | 1 | 2021 | 2 | 0.190 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2021 | 6 | 0.190 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 2 | 0.190 |
Why?
|
| Homeodomain Proteins | 3 | 2015 | 20 | 0.190 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2018 | 5 | 0.180 |
Why?
|
| Genetic Counseling | 1 | 2020 | 9 | 0.180 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 17 | 0.180 |
Why?
|
| Cholesterol, LDL | 1 | 2020 | 7 | 0.180 |
Why?
|
| Receptors, Estrogen | 3 | 2020 | 4 | 0.180 |
Why?
|
| Cholesterol, HDL | 1 | 2020 | 10 | 0.180 |
Why?
|
| Cells, Cultured | 2 | 2018 | 84 | 0.180 |
Why?
|
| Recurrence | 3 | 2016 | 110 | 0.180 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 7 | 0.180 |
Why?
|
| Exome | 3 | 2016 | 36 | 0.180 |
Why?
|
| Voriconazole | 1 | 2019 | 1 | 0.180 |
Why?
|
| Nonlinear Dynamics | 1 | 2019 | 1 | 0.170 |
Why?
|
| Mycoses | 1 | 2019 | 12 | 0.170 |
Why?
|
| Histone Demethylases | 1 | 2019 | 2 | 0.170 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2019 | 4 | 0.170 |
Why?
|
| Breast Implants | 1 | 2019 | 1 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2019 | 13 | 0.170 |
Why?
|
| Recreation | 2 | 2016 | 3 | 0.170 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2019 | 3 | 0.170 |
Why?
|
| Mammaplasty | 1 | 2019 | 3 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 4 | 0.170 |
Why?
|
| Referral and Consultation | 1 | 2019 | 32 | 0.170 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 4 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2019 | 60 | 0.170 |
Why?
|
| Hypertension | 3 | 2009 | 66 | 0.170 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2016 | 8 | 0.170 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2016 | 11 | 0.170 |
Why?
|
| Child, Preschool | 3 | 2022 | 1569 | 0.160 |
Why?
|
| Mosaicism | 2 | 2016 | 9 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 3 | 0.160 |
Why?
|
| Artifacts | 1 | 2018 | 7 | 0.160 |
Why?
|
| RNA, Antisense | 1 | 2018 | 4 | 0.160 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2018 | 2 | 0.160 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 1 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 8 | 0.160 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2018 | 1 | 0.160 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2018 | 1 | 0.160 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2018 | 2 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 115 | 0.160 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2008 | 3 | 0.160 |
Why?
|
| Sumoylation | 1 | 2018 | 1 | 0.160 |
Why?
|
| Cytokines | 1 | 2018 | 48 | 0.160 |
Why?
|
| Ubiquitination | 1 | 2018 | 7 | 0.160 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2016 | 3 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2018 | 3 | 0.160 |
Why?
|
| Factor V | 1 | 2018 | 3 | 0.160 |
Why?
|
| Epidemiologic Research Design | 1 | 2018 | 1 | 0.160 |
Why?
|
| Likelihood Functions | 1 | 2018 | 6 | 0.160 |
Why?
|
| Body Height | 1 | 2018 | 34 | 0.150 |
Why?
|
| Radiotherapy | 1 | 2018 | 5 | 0.150 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 7 | 0.150 |
Why?
|
| Uracil | 2 | 2008 | 2 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2016 | 41 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2019 | 184 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 3 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 46 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 4 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 6 | 2014 | 115 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 42 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2015 | 28 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2014 | 4 | 0.150 |
Why?
|
| DNA Mismatch Repair | 2 | 2014 | 4 | 0.140 |
Why?
|
| DNA | 2 | 2014 | 41 | 0.140 |
Why?
|
| Cadherins | 1 | 2016 | 7 | 0.140 |
Why?
|
| RNA Editing | 1 | 2016 | 2 | 0.140 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2016 | 2 | 0.140 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 3 | 0.140 |
Why?
|
| Biotinidase | 1 | 2016 | 1 | 0.140 |
Why?
|
| Keratin-13 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Actins | 1 | 2016 | 5 | 0.140 |
Why?
|
| Vitamin D | 1 | 2016 | 22 | 0.140 |
Why?
|
| Receptor, Melanocortin, Type 2 | 1 | 2016 | 2 | 0.140 |
Why?
|
| Immunohistochemistry | 4 | 2023 | 48 | 0.140 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 3 | 0.140 |
Why?
|
| Systems Biology | 1 | 2016 | 4 | 0.140 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2016 | 1 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2016 | 2 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2016 | 35 | 0.130 |
Why?
|
| Social Class | 1 | 2016 | 11 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 14 | 0.130 |
Why?
|
| Peptides | 1 | 2016 | 11 | 0.130 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2015 | 1 | 0.130 |
Why?
|
| Glycine N-Methyltransferase | 2 | 2012 | 2 | 0.130 |
Why?
|
| Methionine | 2 | 2012 | 6 | 0.130 |
Why?
|
| RNA Helicases | 1 | 2015 | 2 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 18 | 0.130 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2015 | 1 | 0.130 |
Why?
|
| Infant | 2 | 2018 | 1446 | 0.130 |
Why?
|
| Base Sequence | 5 | 2015 | 81 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 41 | 0.130 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 7 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 2015 | 35 | 0.130 |
Why?
|
| Gonadotropins | 1 | 2014 | 5 | 0.120 |
Why?
|
| Paclitaxel | 4 | 2020 | 4 | 0.120 |
Why?
|
| Genome | 3 | 2012 | 32 | 0.120 |
Why?
|
| Folate Receptor 1 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2018 | 816 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2012 | 10 | 0.120 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 4 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2014 | 25 | 0.120 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 71 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2012 | 3 | 0.120 |
Why?
|
| Lod Score | 2 | 2012 | 2 | 0.120 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2014 | 3 | 0.120 |
Why?
|
| Cell Line, Transformed | 2 | 2010 | 5 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 1 | 0.120 |
Why?
|
| Microsatellite Repeats | 2 | 2011 | 7 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 12 | 0.120 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 1 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 84 | 0.120 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2013 | 1 | 0.120 |
Why?
|
| Lamin Type B | 1 | 2013 | 1 | 0.120 |
Why?
|
| Multigene Family | 1 | 2013 | 8 | 0.120 |
Why?
|
| Environment | 2 | 2010 | 8 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 12 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2022 | 120 | 0.110 |
Why?
|
| Phylogeny | 1 | 2013 | 24 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 1 | 2013 | 1 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2013 | 9 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 16 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 52 | 0.110 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2013 | 1 | 0.110 |
Why?
|
| Telomere | 1 | 2013 | 3 | 0.110 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2013 | 19 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 3 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2013 | 7 | 0.110 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 14 | 0.110 |
Why?
|
| Drug Therapy | 2 | 2009 | 7 | 0.110 |
Why?
|
| Complement C3 | 2 | 2010 | 3 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 3 | 0.110 |
Why?
|
| Oligodendroglioma | 1 | 2012 | 2 | 0.110 |
Why?
|
| ABO Blood-Group System | 1 | 2012 | 11 | 0.110 |
Why?
|
| RNA Interference | 4 | 2015 | 16 | 0.110 |
Why?
|
| Methionine Adenosyltransferase | 1 | 2012 | 1 | 0.110 |
Why?
|
| Genes | 1 | 2012 | 10 | 0.100 |
Why?
|
| Ligands | 1 | 2012 | 5 | 0.100 |
Why?
|
| Mammary Glands, Human | 1 | 2012 | 2 | 0.100 |
Why?
|
| Glycine Dehydrogenase | 1 | 2012 | 1 | 0.100 |
Why?
|
| Glycine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2012 | 1 | 0.100 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2012 | 1 | 0.100 |
Why?
|
| Mitosis | 1 | 2012 | 2 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2011 | 7 | 0.100 |
Why?
|
| Nephroblastoma Overexpressed Protein | 1 | 2011 | 1 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2011 | 3 | 0.100 |
Why?
|
| Myocardial Infarction | 2 | 2011 | 5 | 0.100 |
Why?
|
| CD30 Ligand | 1 | 2011 | 1 | 0.100 |
Why?
|
| Mice | 2 | 2024 | 348 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2022 | 18 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2011 | 1 | 0.100 |
Why?
|
| Vincristine | 2 | 2022 | 6 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2011 | 2 | 0.100 |
Why?
|
| Genes, Mitochondrial | 1 | 2011 | 1 | 0.100 |
Why?
|
| Mycophenolic Acid | 1 | 2011 | 6 | 0.100 |
Why?
|
| ras Proteins | 1 | 2011 | 1 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Transfection | 4 | 2012 | 22 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 18 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 14 | 0.100 |
Why?
|
| Xenobiotics | 1 | 2010 | 3 | 0.090 |
Why?
|
| Imines | 1 | 2010 | 3 | 0.090 |
Why?
|
| Benzoquinones | 1 | 2010 | 3 | 0.090 |
Why?
|
| Betaine-Homocysteine S-Methyltransferase | 1 | 2010 | 2 | 0.090 |
Why?
|
| Acetaminophen | 1 | 2010 | 18 | 0.090 |
Why?
|
| Radiation | 1 | 2010 | 1 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 2011 | 56 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 7 | 0.090 |
Why?
|
| Regression Analysis | 3 | 2018 | 52 | 0.090 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2010 | 4 | 0.090 |
Why?
|
| Aromatase Inhibitors | 1 | 2010 | 1 | 0.090 |
Why?
|
| Tissue Array Analysis | 3 | 2014 | 5 | 0.090 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2010 | 17 | 0.090 |
Why?
|
| TCF Transcription Factors | 1 | 2009 | 1 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 4 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 1 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2016 | 9 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 3 | 2016 | 3 | 0.080 |
Why?
|
| Uric Acid | 1 | 2009 | 6 | 0.080 |
Why?
|
| Molecular Epidemiology | 1 | 2009 | 6 | 0.080 |
Why?
|
| Chromosomes, Human, X | 2 | 2019 | 6 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2016 | 25 | 0.080 |
Why?
|
| Hydrochlorothiazide | 1 | 2008 | 2 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 71 | 0.080 |
Why?
|
| Eye | 1 | 2008 | 3 | 0.080 |
Why?
|
| Dacarbazine | 2 | 2022 | 3 | 0.080 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2008 | 1 | 0.080 |
Why?
|
| Postmenopause | 2 | 2020 | 6 | 0.080 |
Why?
|
| Phenylethanolamine N-Methyltransferase | 1 | 2008 | 1 | 0.080 |
Why?
|
| Epinephrine | 1 | 2008 | 7 | 0.080 |
Why?
|
| Antigens, Differentiation | 1 | 2008 | 1 | 0.080 |
Why?
|
| Aging | 1 | 2008 | 39 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2008 | 13 | 0.080 |
Why?
|
| Amidohydrolases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Genes, Reporter | 3 | 2015 | 13 | 0.080 |
Why?
|
| Toll-Like Receptors | 1 | 2008 | 14 | 0.080 |
Why?
|
| HeLa Cells | 3 | 2014 | 17 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2007 | 10 | 0.080 |
Why?
|
| MCF-7 Cells | 2 | 2021 | 4 | 0.080 |
Why?
|
| Data Collection | 1 | 2007 | 29 | 0.070 |
Why?
|
| Ovary | 3 | 2013 | 6 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 119 | 0.070 |
Why?
|
| Neutropenia | 2 | 2019 | 12 | 0.070 |
Why?
|
| Quality of Life | 2 | 2022 | 140 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2017 | 25 | 0.070 |
Why?
|
| Chromatin | 2 | 2018 | 22 | 0.070 |
Why?
|
| Chromatography, Thin Layer | 2 | 2015 | 3 | 0.070 |
Why?
|
| Hyperplasia | 2 | 2015 | 5 | 0.070 |
Why?
|
| Precancerous Conditions | 2 | 2015 | 6 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2015 | 19 | 0.070 |
Why?
|
| Registries | 3 | 2013 | 92 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 5 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2015 | 58 | 0.060 |
Why?
|
| Demography | 2 | 2019 | 8 | 0.060 |
Why?
|
| Age Factors | 2 | 2016 | 210 | 0.060 |
Why?
|
| Global Health | 2 | 2015 | 15 | 0.060 |
Why?
|
| Epigenomics | 2 | 2016 | 27 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2015 | 28 | 0.060 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 8 | 0.060 |
Why?
|
| Apoptosis | 2 | 2016 | 52 | 0.060 |
Why?
|
| Cell Movement | 2 | 2016 | 71 | 0.060 |
Why?
|
| Meninges | 1 | 2024 | 1 | 0.060 |
Why?
|
| Protein Binding | 2 | 2015 | 31 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2024 | 6 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 24 | 0.060 |
Why?
|
| Adult Children | 1 | 2003 | 1 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 4 | 0.060 |
Why?
|
| Systole | 1 | 2003 | 10 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2003 | 22 | 0.060 |
Why?
|
| Coculture Techniques | 1 | 2023 | 4 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 1 | 0.060 |
Why?
|
| DNA Polymerase III | 1 | 2023 | 1 | 0.060 |
Why?
|
| Melphalan | 1 | 2023 | 1 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2023 | 4 | 0.060 |
Why?
|
| Estrogens | 1 | 2023 | 3 | 0.060 |
Why?
|
| Datasets as Topic | 1 | 2023 | 7 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2003 | 67 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2023 | 15 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2023 | 1 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2003 | 2 | 0.060 |
Why?
|
| Cell Survival | 2 | 2015 | 20 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 2 | 2015 | 3 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 99 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2013 | 32 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 31 | 0.050 |
Why?
|
| Camptothecin | 1 | 2022 | 1 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 1 | 0.050 |
Why?
|
| Depression | 1 | 2023 | 69 | 0.050 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2022 | 4 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2022 | 9 | 0.050 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 2 | 2014 | 5 | 0.050 |
Why?
|
| Heterozygote | 2 | 2015 | 26 | 0.050 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2014 | 5 | 0.050 |
Why?
|
| Chromosome Deletion | 2 | 2014 | 20 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2016 | 137 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 9 | 0.050 |
Why?
|
| Language | 1 | 2022 | 4 | 0.050 |
Why?
|
| HapMap Project | 2 | 2012 | 3 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2022 | 59 | 0.050 |
Why?
|
| Cooperative Behavior | 2 | 2013 | 24 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 150 | 0.050 |
Why?
|
| Methyltransferases | 2 | 2011 | 9 | 0.050 |
Why?
|
| Glycolysis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2012 | 2 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2012 | 17 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2021 | 45 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 4 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 46 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2011 | 12 | 0.050 |
Why?
|
| Albumins | 1 | 2020 | 7 | 0.050 |
Why?
|
| COS Cells | 2 | 2012 | 19 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2020 | 2 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2020 | 3 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 6 | 0.040 |
Why?
|
| Australia | 2 | 2010 | 10 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 33 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 146 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2020 | 4 | 0.040 |
Why?
|
| Europe | 2 | 2010 | 37 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 7 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2019 | 4 | 0.040 |
Why?
|
| Insurance Carriers | 1 | 2019 | 2 | 0.040 |
Why?
|
| Risk Management | 1 | 2019 | 1 | 0.040 |
Why?
|
| Hydrazines | 1 | 2019 | 1 | 0.040 |
Why?
|
| Histone Deacetylases | 1 | 2019 | 2 | 0.040 |
Why?
|
| Depsipeptides | 1 | 2019 | 2 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 8 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 4 | 0.040 |
Why?
|
| Breast | 1 | 2019 | 4 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 11 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2019 | 10 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2019 | 6 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 15 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 35 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 25 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 187 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 133 | 0.040 |
Why?
|
| Patient Selection | 1 | 2019 | 40 | 0.040 |
Why?
|
| Hydro-Lyases | 1 | 2018 | 2 | 0.040 |
Why?
|
| CTLA-4 Antigen | 2 | 2008 | 3 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 2 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 32 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 4 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2018 | 22 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2017 | 3 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 17 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2017 | 15 | 0.040 |
Why?
|
| Breath Tests | 2 | 2008 | 11 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2008 | 40 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 2 | 0.040 |
Why?
|
| Waist-Hip Ratio | 1 | 2016 | 1 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 4 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 8 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 22 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Premenopause | 1 | 2015 | 3 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 7 | 0.030 |
Why?
|
| Nuchal Cord | 1 | 2015 | 1 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 24 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 2015 | 1 | 0.030 |
Why?
|
| Fixatives | 1 | 2015 | 2 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2015 | 4 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 11 | 0.030 |
Why?
|
| Diterpenes | 1 | 2015 | 1 | 0.030 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2015 | 1 | 0.030 |
Why?
|
| Epoxy Compounds | 1 | 2015 | 1 | 0.030 |
Why?
|
| Phenanthrenes | 1 | 2015 | 1 | 0.030 |
Why?
|
| Tripterygium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2015 | 1 | 0.030 |
Why?
|
| RNA Splicing | 1 | 2015 | 14 | 0.030 |
Why?
|
| Biological Transport | 1 | 2015 | 19 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2014 | 3 | 0.030 |
Why?
|
| Folic Acid Deficiency | 1 | 2014 | 3 | 0.030 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 2 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2014 | 2 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2014 | 2 | 0.030 |
Why?
|
| Neutrophils | 1 | 2014 | 11 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 11 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 23 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 28 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2014 | 1 | 0.030 |
Why?
|
| Mannosyltransferases | 1 | 2014 | 1 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 2 | 0.030 |
Why?
|
| Uniparental Disomy | 1 | 2014 | 1 | 0.030 |
Why?
|
| Energy Intake | 1 | 2014 | 34 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 1 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 52 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 12 | 0.030 |
Why?
|
| Chromosome Disorders | 1 | 2014 | 7 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 12 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 16 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 9 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 2 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 6 | 0.030 |
Why?
|
| Nucleotide Motifs | 1 | 2013 | 3 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2013 | 18 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2013 | 51 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2013 | 29 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2012 | 5 | 0.030 |
Why?
|
| S-Adenosylmethionine | 1 | 2012 | 1 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2012 | 6 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2012 | 5 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 1 | 0.030 |
Why?
|
| Mammography | 1 | 2012 | 2 | 0.030 |
Why?
|
| Biopsy | 1 | 2012 | 60 | 0.030 |
Why?
|
| North America | 1 | 2012 | 44 | 0.030 |
Why?
|
| Family | 1 | 2012 | 27 | 0.030 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2012 | 5 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2012 | 7 | 0.030 |
Why?
|
| Citalopram | 1 | 2012 | 14 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2011 | 6 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2011 | 6 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2011 | 12 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 15 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2011 | 1 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2011 | 1 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2011 | 3 | 0.020 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2011 | 1 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 26 | 0.020 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cytochrome b Group | 1 | 2011 | 1 | 0.020 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2011 | 1 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2011 | 3 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 5 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
| Oxidoreductases | 1 | 2011 | 9 | 0.020 |
Why?
|
| Autoantigens | 1 | 2011 | 5 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 10 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2011 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 10 | 0.020 |
Why?
|
| Peptide Termination Factors | 1 | 2010 | 1 | 0.020 |
Why?
|
| Quinone Reductases | 1 | 2010 | 1 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2010 | 2 | 0.020 |
Why?
|
| Epoxide Hydrolases | 1 | 2010 | 6 | 0.020 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2010 | 4 | 0.020 |
Why?
|
| Glutathione | 1 | 2010 | 11 | 0.020 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2010 | 18 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 2 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2010 | 1 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 3 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 4 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 13 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 9 | 0.020 |
Why?
|
| Fetus | 1 | 2010 | 16 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2010 | 1 | 0.020 |
Why?
|
| Carbon-Nitrogen Ligases | 1 | 2010 | 1 | 0.020 |
Why?
|
| Gestational Age | 1 | 2010 | 62 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 12 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 7 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2009 | 1 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2009 | 2 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 20 | 0.020 |
Why?
|
| Cyclin E | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2009 | 2 | 0.020 |
Why?
|
| North Carolina | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Minnesota | 1 | 2009 | 6 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2009 | 11 | 0.020 |
Why?
|
| Kidney | 1 | 2009 | 94 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 52 | 0.020 |
Why?
|
| 3' Flanking Region | 1 | 2008 | 1 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2008 | 14 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 15 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 274 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2008 | 8 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2008 | 9 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2008 | 12 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2008 | 14 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 14 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 44 | 0.020 |
Why?
|
| Guanine | 1 | 2008 | 1 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cytosine | 1 | 2008 | 5 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2008 | 3 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 39 | 0.020 |
Why?
|
| Rats | 1 | 2008 | 106 | 0.020 |
Why?
|
| Thrombocythemia, Essential | 1 | 2007 | 1 | 0.020 |
Why?
|
| Polycythemia Vera | 1 | 2007 | 2 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 6 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2008 | 47 | 0.020 |
Why?
|
| Methods | 1 | 2003 | 4 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 10 | 0.010 |
Why?
|